<--GAT-->
Clinical Topics

VA Research Determines Which Beta Blocker Is Better in Heart Failure

by Brenda Mooney

September 9, 2018

ST. LOUIS—Current clinical guidelines recommend the use of beta blockers in all heart failure patients with with reduced ejection fraction (HFrEF).

Which beta blocker to use—carvedilol or metoprolol succinate—remained unclear, however, according to a recent article in the American Heart Journal. To help answer that question, St. Louis University School of Medicine and Richard L. Roudebush VAMC researchers sought to compare survival benefit of carvedilol to metoprolol succinate.1

The study team queried the VA database to identify 114,745 patients diagnosed with HFrEF from 2007 to 2015 who were prescribed carvedilol and metoprolol succinate. Carvedilol and metoprolol patients—nearly 44,000 of each—were compared and analysis was used to calculate survival probability and hazard ratio.

At the same time, subgroup analyses were carried out separately for men, women, elderly veterans, those with duration of therapy of more than three months, and diabetic patients.

Results indicated that the adjusted hazard ratio of mortality for metoprolol succinate compared to carvedilol was 1.069 (95% CI: 1.046-1.092, P value: < 0.001). The carvedilol group had higher survival probability at six years compared to the metoprolol succinate group (55.6% vs 49.2%, P value < 0.001).

The difference remained after subgroup analysis for males, patients of any age, those undergoing therapy for more than three months and nondiabetic patients, the researchers reported.

“Patients with HFrEF taking carvedilol had improved survival as compared to metoprolol succinate,” study authors concluded. “The data supports the need for furthering testing to determine optimal choice of beta blockers in patients with heart failure with reduced ejection fraction.”

Whatever the beta blockers used, the same researchers determined in another study that more appeared to be better. That report, published in the American Journal of Cardiology, also looked at the veteran population to determine optimal beta blocker use in HFrEF in atrial fibrillation (AF).2

All patients diagnosed with HFrEF from 2007 to 2015 in AF were identified through the VA databases, and 12,232 patients on low dose beta blocker—carvedilol or metoprolol succinate—were matched with as many patients on high dose beta-blocker using propensity score matching.

Researchers determined that high doses of beta blockers were associated with lower overall mortality as compared to low doses (HR: 0.77, 95% CI: 0.74-0.80, p<0.01). “Higher dose of beta blocker therapy and a lower achieved [heart rate] were both associated with a reduction in mortality in HFrEF patients with AF,” the study authors concluded.

1. Ajam T, Ajam S, Devaraj S, Mohammed K, Sawada S, Kamalesh M. Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction. Am Heart J. 2018 May;199:1-6. doi: 10.1016/j.ahj.2018.01.005. Epub 2018 Jan 31. PubMed PMID: 29754646.

2. Ajam T, Ajam S, Devaraj S, Fudim M, Kamalesh M. Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure. Am J Cardiol.em> 2018 Jun 21. pii: S0002-9149(18)31221-9. doi: 10.1016/j.amjcard.2018.05.038. [Epub ahead of print] PubMed PMID: 30049457.


Related Articles

“Coming together is a beginning. Keeping together is progress. Working together is success.” — Henry Ford (1863-1947)

October is Operation Bushmaster season for Uniformed Services University (USU) medical and nursing students.

NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.


U.S. Medicine Recommends


More From cardiology

Cardiology

NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.

Cardiology

New VA Analysis Refutes Link Between Heart Failure, Incident Cancer

With about 350,000 patients with heart failure diagnoses being treated in the VHA, recent studies suggesting that the cardiovascular condition increases risk of cancer have been worrisome.

Cardiology

Medications, interventions underused in veterans with peripheral artery disease

Nearly 30% of veterans with peripheral artery disease (PAD) die within four years of diagnosis, while others experience limb amputation or critical limb ischemia.

Cardiology

Rank as socioeconomic proxy affects stroke outcomes in MHS patients

Do socioeconomic disparities exist in the U.S. military healthcare system with ischemic stroke admissions? A new study says they do.

Cardiology

In-Hospital Cardiac Arrest Has Higher Survival Rates at VA Hospitals

Veterans who suffer cardiac arrest during a VA hospital stay are more likely to survive the experience than patients who have such events cardiac arrests in other U.S. hospitals. And, a year later, they are also more likely to still be alive.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up